SUVEN PHARMACEUTICALS SHARE PRICE
![Shark tank fame Namita Thapar shares an emotional Mirza Ghalib shayari post Emcure IPO's robust listing](https://img.etimg.com/thumb/msid-111665801,width-100,height-75,resizemode-4/markets/stocks/news/shark-tank-fame-namita-thapar-shares-an-emotional-mirza-ghalib-shayari-post-emcure-ipos-robust-listing.jpg)
Shark tank fame Namita Thapar shares an emotional Mirza Ghalib shayari post Emcure IPO's robust listing
The robust listing met expectations, reflecting the company's long-term potential. Analysts recommend that investors maintain their positions for promising future returns.
![Promoters to sell 7.85% in Glenmark Life through OFS](https://img.etimg.com/thumb/msid-111640102,width-100,height-75,resizemode-4/markets/stocks/news/promoters-to-sell-7-85-in-glenmark-life-through-ofs.jpg)
Promoters to sell 7.85% in Glenmark Life through OFS
The OFS will be open for non-retail investors on Thursday, with retail investors allowed to place their bids on Friday. A minimum of 10% of the OFS has been reserved for the retail category, subject to receipt of valid bids.
![Emcure Pharma shares jump over 4% post listing. Should you buy, sell or hold?](https://img.etimg.com/thumb/msid-111627691,width-100,height-75,resizemode-4/markets/stocks/news/emcure-pharma-shares-jump-over-4-post-listing-should-you-buy-sell-or-hold.jpg)
Emcure Pharma shares jump over 4% post listing. Should you buy, sell or hold?
Pune-based Emcure Pharmaceuticals listed at Rs 1,325, a 31.4% premium on Rs 1,008 IPO price. QIBs subscribed 195.8 times, non-institutional investors 48.3 times. Analysts recommend long-term holding. IPO proceeds target debt and corporate purposes. Offering products in therapeutic areas, Emcure recorded Rs 6,658 crore revenue in FY24 and operates in Europe, Canada.
![Emcure Pharma shares debut with 31% premium over issue price](https://img.etimg.com/thumb/msid-111622266,width-100,height-75,resizemode-4/markets/stocks/news/emcure-pharma-shares-debut-with-31-premium-over-issue-price.jpg)
Emcure Pharma shares debut with 31% premium over issue price
Before listing, the company's shares traded at a Rs 360 premium in the grey market. It raised Rs 582 crore from anchor investors, including HDFC MF, ICICI Pru MF, SBI MF, Abu Dhabi Investment Authority, Goldman Sachs Asset Management, Nomura, and HDFC Life. Analysts are bullish on the IPO for listing gains and long-term growth, citing its strong position in domestic therapeutics and expansion plans in India and exports.
![Emcure Pharma IPO GMP rises on share allotment day, indicating healthy listing](https://img.etimg.com/thumb/msid-111580280,width-100,height-75,resizemode-4/markets/ipos/fpos/emcure-pharma-ipo-gmp-rises-on-share-allotment-day-indicating-healthy-listing.jpg)
Emcure Pharma IPO GMP rises on share allotment day, indicating healthy listing
Following a healthy response to the IPO of Emcure Pharmaceuticals, the shares of the company are commanding a healthy premium of Rs 360 in the unlisted market.
Emcure Pharmaceuticals IPO booked nearly 68 times so far on Day 3. Check GMP and other details
Emcure Pharmaceuticals IPO sees strong demand with oversubscription. Anchor investors include top names. Company engaged in global pharmaceutical products. Revenue growth and plans for debt payment outlined. Book-running lead managers identified.
Emcure Pharmaceuticals IPO fully subscribed on Day 1. Check GMP and other details
Emcure Pharmaceuticals' IPO attracts high demand from investors, with a price range of Rs 960-1008 per share. Analysts foresee business improvements and revenue growth potential in the global pharmaceutical market, supporting the company's expansion strategies.
Emcure Pharmaceuticals IPO booked nearly 5x so far on Day 2. Check GMP and other details
Emcure Pharmaceuticals' IPO has been oversubscribed nearly three times as of Thursday, the second day of bidding. The bidding concludes on July 5. The categories reserved for NII and retail investors were subscribed the most at 13 times and 3.43 times, respectively.
Namita Thapar's Emcure Pharmaceuticals IPO opens on Wednesday. What GMP signals ahead of subscription
Emcure Pharmaceuticals' IPO opens for subscription on July 3rd with shares trading at a Rs 265 premium in the unlisted market. The IPO includes fresh equity shares worth Rs 800 crore and an Offer For Sale (OFS) of 1.14 crore shares. Priced at Rs 960-1,008 per share, investors can bid for 14 shares per lot. The company targets to raise Rs 1,952 crore at the upper price range.
Kotak Equities initiates coverage on JB Chemicals with a target price of Rs 2,025
“Having primarily grown organically until FY2022 and later on aided by benefits from acquired brands, JB has handsomely outperformed the IPM in the past decade by ~600 bps and currently ranks 22 in the IPM,” said Alankar Garude, Analyst at Kotak Equities.
Emcure Pharmaceuticals IPO: 10 things to know before subscribing to the issue
Emcure Pharmaceuticals IPO is scheduled to open for subscription on July 3 and will close on July 5. The company aims to raise approximately Rs 1,952 crore through the public offer. Market analysts indicate that the current GMP of the pharma company stands at Rs 260 in the unlisted market.
Excited about gain in market share in US, says Biocon chief Kiran Mazumdar Shaw
Biocon Executive Chairperson Kiran Mazumdar Shaw say we've seen significant market share growth for our biosimilars in the US, exceeding our 20% global insulin market target sooner than expected. Demand has surged, especially for insulins, creating substantial opportunities.
Dr Reddy's signs in-licensing pact with Ingenus Pharmaceuticals for cancer treatment injection
Dr Reddy's Laboratories Ltd has signed a licensing agreement with US-based Ingenus Pharmaceuticals to commercialize Cyclophosphamide injection for cancer treatment. Dr Reddy's USA will commercialize the injection in the US market, paying Ingenus 50% of the calculated profit share.
GSM Foils shares list at IPO price on NSE SME platform
GSM Foils Share Price: GSM Foils lists on NSE SME at Rs 32 per share, with healthy IPO response of 250 times subscription. The company manufactures Blister Foils and Aluminium Pharma Foils for pharmaceutical packaging, capitalizing on India's robust pharmaceutical industry.
Sun Pharma shares tumble 5% but brokerages raise target up to Rs 1,785. Should you buy, sell or hold?
In Thursday's trading session on the BSE, shares of Sun Pharmaceutical Industries declined by 5%, reaching the day's low of Rs 1,467. This drop occurred despite the company reporting a 34% year-on-year (YoY) increase in its Q4 profit to Rs 2,654.6 crore, with revenue rising by 10.1% YoY to Rs. 11,813 crore in Q4FY24.
Merger effect! Suven Pharma shares jump 15% in 2 days
After the merger becomes effective, all shareholders of Cohance will be issued shares of Suven at the ratio of 11 shares of Suven for every 295 shares of Cohance, based on the swap ratio. The new shares of Suven will be traded on the NSE and BSE.
Suven Pharmaceuticals shares soar 13% on proposed merger with Cohance Lifesciences
Shares of Suven Pharmaceuticals surged 13% on the NSE after proposing a merger with Cohance Lifesciences to strengthen its CDMO industry position. After the merger, Advent entities will own 66.7%, and the transaction is expected to conclude in 12-15 months.
JSW Steel shares jump 4%, market cap crosses Rs 2 lakh crore mark. Here’s why
JSW Steel's shares rose 4.4% as it incorporated JSW Green Steel Ltd for steel product manufacturing. Its market cap surpassed Rs 2 lakh crore, making it the top Nifty gainer. The stock has delivered nearly 23% in the last 12 months, underperforming Nifty50.
Load More